Dual-targeted therapy with ustekinumab and vedolizumab as a novel rescue strategy: achieving high clinical response rates in Crohn's disease refractory to both monotherapies.
BACKGROUND Managing Crohn's disease is challenging as a substantial proportion of patients lose response to biologics. This study evaluated dual targeted therapy (DTT) with ustekinumab (UST) and vedolizumab (VDZ) in patients refractory to both agents as monotherapies. METHODS This retrospective study enrolled 23 pati...